CA3111216A1 - Peptide therapeutics for the treatment of cancer and uses thereof - Google Patents

Peptide therapeutics for the treatment of cancer and uses thereof Download PDF

Info

Publication number
CA3111216A1
CA3111216A1 CA3111216A CA3111216A CA3111216A1 CA 3111216 A1 CA3111216 A1 CA 3111216A1 CA 3111216 A CA3111216 A CA 3111216A CA 3111216 A CA3111216 A CA 3111216A CA 3111216 A1 CA3111216 A1 CA 3111216A1
Authority
CA
Canada
Prior art keywords
peptide
sequence
seq
isolated peptide
modulating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3111216A
Other languages
English (en)
French (fr)
Inventor
Keith Scott Robinson
Wei Luo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Microquin Ltd
Original Assignee
Microquin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Microquin Ltd filed Critical Microquin Ltd
Publication of CA3111216A1 publication Critical patent/CA3111216A1/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1761Apoptosis related proteins, e.g. Apoptotic protease-activating factor-1 (APAF-1), Bax, Bax-inhibitory protein(s)(BI; bax-I), Myeloid cell leukemia associated protein (MCL-1), Inhibitor of apoptosis [IAP] or Bcl-2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747Apoptosis related proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3111216A 2018-08-27 2019-08-27 Peptide therapeutics for the treatment of cancer and uses thereof Pending CA3111216A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862723428P 2018-08-27 2018-08-27
US62/723,428 2018-08-27
PCT/US2019/048414 WO2020046997A1 (en) 2018-08-27 2019-08-27 Peptide therapeutics for the treatment of cancer and uses thereof

Publications (1)

Publication Number Publication Date
CA3111216A1 true CA3111216A1 (en) 2020-03-05

Family

ID=69643321

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3111216A Pending CA3111216A1 (en) 2018-08-27 2019-08-27 Peptide therapeutics for the treatment of cancer and uses thereof

Country Status (12)

Country Link
US (1) US20210361742A1 (zh)
EP (1) EP3844262A4 (zh)
JP (1) JP2021534826A (zh)
KR (1) KR20210097690A (zh)
CN (1) CN113195704A (zh)
AU (1) AU2019327424A1 (zh)
BR (1) BR112021003812A2 (zh)
CA (1) CA3111216A1 (zh)
IL (1) IL281091A (zh)
MX (1) MX2021002245A (zh)
SG (1) SG11202101945PA (zh)
WO (1) WO2020046997A1 (zh)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2081954B1 (de) * 2006-10-24 2012-06-13 BASF Plant Science GmbH Verfahren zur erhöhung der resistenz gegen biotrophe pilze in pflanzen

Also Published As

Publication number Publication date
JP2021534826A (ja) 2021-12-16
MX2021002245A (es) 2021-08-11
SG11202101945PA (en) 2021-03-30
BR112021003812A2 (pt) 2021-07-27
WO2020046997A1 (en) 2020-03-05
IL281091A (en) 2021-04-29
CN113195704A (zh) 2021-07-30
AU2019327424A1 (en) 2021-04-15
US20210361742A1 (en) 2021-11-25
EP3844262A1 (en) 2021-07-07
EP3844262A4 (en) 2022-09-14
KR20210097690A (ko) 2021-08-09

Similar Documents

Publication Publication Date Title
DK2760463T3 (en) REGULATION OF SODIUM CHANNELS USING PLUNC PROTEINS
CA2927592C (en) Fgf-19 variants for treating a fgf-19 dependent cancer or tumor
JP6486908B2 (ja) 肝細胞増殖因子に結合する設計アンキリン反復タンパク質
JP2017528449A (ja) アミロイドーシスのための標的化免疫療法
US20200362017A1 (en) Mimetic peptides derived from collagen type iv and their use for treating angiogenesis- and lymphangiogenesis- dependent diseases
EP1856145B1 (en) Voltage dependent anion channel (vdac1) compositions and methods of use thereof for regulating apoptosis
US9388213B2 (en) Polycomb repressive complex 2 (PRC2) inhibitors and uses thereof
US9254309B2 (en) Use of multivalent synthetic ligands of surface nucleolin for treating cancer or inflammation
US10314883B2 (en) Compositions and methods for regulating blood pressure
PT2352508E (pt) Péptidos do domínio citoplasmático muc1 como inibidores de cancro
AU2015250039B2 (en) TRAIL receptor agonists for treatment of fibrotic diseases
JP7028904B2 (ja) 合成ペプチド、それを備える薬学的組成物及び血栓塞栓症関連疾患の治療におけるその使用
JP2013535954A (ja) ペプチド、構造体およびその使用
WO2013142965A1 (en) Sh2 domain variants
US10106590B2 (en) BH4 stabilized peptides and uses thereof
US20220242964A1 (en) Compositions and methods for regulating erythropoiesis
KR101947529B1 (ko) Rhamm 결합 펩타이드
US8648045B2 (en) VDAC1 compositions and methods of use thereof for regulating apoptosis
JP2024038022A (ja) 改良された抗老化化合物及びその癌処置のための使用
US20210361742A1 (en) Peptide therapeutics for the treatment of cancer and uses thereof
WO2013163431A1 (en) Diagnosis and treatment of brain tumor
US20140005119A1 (en) COMPOSITIONS AND METHODS FOR INHIBITING THE ACTIVITY OF P110a MUTANT PROTEINS
JP2023546383A (ja) アネキシンa5組成物及び方法